Virucidal Gargle Composition for Lipid-Enveloped Virus Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for influenza and other enveloped viruses are inadequate, often focusing on symptom relief rather than virus eradication, and vaccines have limitations in effectiveness and potential side effects, necessitating a virucidal composition for effective prevention and treatment.
Innovation Solution
A topical mucosal composition containing citron, lemon, lime, plant acids, vinegar, garlic, gangmei root, Sambucus nigra, Pelargonium sidoides, cranberry or pomegranate juice, zinc, saponified lipid, non-toxic detergent, and vitamin C is administered as a gargle, throat spray, or lozenge, targeting the oral mucosa to disrupt the lipid envelope of viruses and prevent replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccines are used for influenza prevention, then immunity is provided, but effectiveness is not 100% and side effects occur
Solution Approach 1:
The patent extracts and targets the specific vulnerable point of enveloped viruses (lipid envelope) for direct destruction, rather than relying on the indirect immune system activation through vaccines. The virucidal composition directly attacks the viral structure, eliminating the need for vaccine-induced immunity and avoiding vaccine side effects while achieving complete viral eradication.
Solution Approach 2:
The patent converts the harmful lipid envelope of viruses into a vulnerable target. By using lipid-dissolving agents (acids, soaps, detergents), the composition transforms the virus's protective lipid layer into its point of weakness, enabling complete viral destruction without the compromises of vaccine-based prevention.
2Ease of operation
If symptom relief treatments are used, then comfort is improved, but virus eradication is not achieved
Solution Approach 1:
The patent applies preliminary action by destroying the viral lipid envelope before the virus can establish infection and cause symptoms. The virucidal composition is administered at the first sign of infection (sore throat), preventing viral replication and symptom development rather than treating symptoms after they occur, thereby achieving both comfort and complete viral eradication.
Solution Approach 2:
The patent converts the virus's lipid envelope, which normally protects the virus and prevents eradication, into its vulnerability point. By using lipid-dissolving agents, the composition turns the virus's protective feature into its weak point, enabling complete destruction without merely suppressing symptoms.
3Reliability
If topical mucosal composition is administered as gargle, then direct viral disruption is achieved, but administration complexity increases
Solution Approach 1:
The patent applies self-service by using the patient's own body fluids (mouthwater, saliva) as the delivery medium for the virucidal composition. The patient simply gargles the composition, and their natural salivary flow distributes the antiviral agents throughout the oral cavity and pharynx, eliminating the need for complex administration devices or techniques while ensuring direct viral contact and disruption.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively reduces the duration and severity of influenza and other lipid-enveloped virus infections by directly targeting and disrupting the viral lipid envelope, providing rapid symptom relief within 12-48 hours and potentially preventing infection.
Implementation Method 1
A topical mucosal composition containing citron, lemon, lime, plant acids, vinegar, garlic, gangmei root, Sambucus nigra, Pelargonium sidoides, cranberry or pomegranate juice, zinc, saponified lipid, non-toxic detergent, and vitamin C is administered as a gargle, throat spray, or lozenge, targeting the oral mucosa to disrupt the lipid envelope of viruses and prevent replication.
Data Source
AI summary
The present invention is a novel approach to treating, and even preventing, upper respiratory infections its related symptoms caused by influenza or other lipid-enveloped viruses infiltration and infection in vivo, comprising administering as a gargling agent one or more of clove (plant parts or oil), black tea (with or without caffeine), at least one fatty acid and/or its mono- or di-glyceride form, such as without limitation, coconut water (milk, cream, oil, etc.), caprylic acid, lauric acid (and glycerol monolaurate), monolaurin, myristic acid, oleic acid, palmitoleic acid, or stearic acid, citron, lemon, lime, plant acids (citric acid, etc.), food grade acids (acetic, lactic, malic, oxalic, benzoic, quinic, tannic, and others and/or their sodium salts), vinegar (apple cider, white, balsamic, red wine, wine, etc.), garlic, gangmei root, Sambucus nigra (elderberry), Pelargonium sidoides and or any extract thereof (African geranium), cranberry or pomegranate juice, zinc, saponified lipid (soap), non-toxic detergent, or vitamin C.